Supernus Pharmaceuticals (NASDAQ:SUPN) VP Padmanabh Bhatt Sells 710 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the transaction, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Supernus Pharmaceuticals Stock Up 4.5%

Shares of SUPN opened at $51.48 on Friday. The firm’s fifty day moving average is $48.27 and its two-hundred day moving average is $42.37. The stock has a market cap of $2.95 billion, a PE ratio of -151.41, a price-to-earnings-growth ratio of 0.60 and a beta of 0.71. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The business had revenue of $170.00 million for the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.69 earnings per share. As a group, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SUPN. Hantz Financial Services Inc. increased its position in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the last quarter. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Smartleaf Asset Management LLC increased its holdings in Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Supernus Pharmaceuticals in the first quarter valued at approximately $46,000. Finally, Vestcor Inc acquired a new position in Supernus Pharmaceuticals during the third quarter worth $67,000.

Analyst Ratings Changes

Several brokerages have issued reports on SUPN. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a report on Tuesday, September 30th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday. TD Cowen lifted their target price on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Finally, Stifel Nicolaus boosted their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.